Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Shattuck Labs's Free Cash Flow for the
three
months ended in Mar. 2026 was $-13.42 Mil. Shattuck Labs's Revenue for the
three
months ended in Mar. 2026 was $0.00 Mil. Therefore, Shattuck Labs's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.
The historical rank and industry rank for Shattuck Labs's FCF Margin % or its related term are showing as below:
STTK'
s FCF Margin % Range Over the Past 10 Years
Min: -16274.85 Med: -702.47 Max: -36.01
Current: -4127.4
During the past 8 years, the highest FCF Margin % of Shattuck Labs was -36.01%. The lowest was -16274.85%. And the median was -702.47%.
STTK's FCF Margin % is ranked worse than 88.74% of 950
companies
in the Biotechnology industry
Industry Median: -81.28
vs STTK: -4127.40
Shattuck Labs FCF Margin % Related Terms
Shattuck Labs FCF Margin % Historical Data
* Premium members only.
The historical data trend for Shattuck Labs's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Shattuck Labs's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shattuck Labs FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shattuck Labs's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Shattuck Labs's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shattuck Labs (STTK) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Shattuck Labs and its competitors. According to the industry distribution chart, Shattuck Labs ranks #843 out of 950 companies in the Biotechnology industry, placing it in the top 88.7%.
Is Shattuck Labs' FCF Margin % too high?
Shattuck Labs' current FCF Margin % is 0.00%. Based on the distribution chart, Shattuck Labs ranks #843 out of 950 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Shattuck Labs has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shattuck Labs' FCF Margin % compare to ACHV and CRMD?
According to the Biotechnology industry distribution chart, Shattuck Labs ranks #843 out of 950 companies for FCF Margin %. This places Shattuck Labs in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Shattuck Labs and its competitors. Shattuck Labs's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shattuck Labs stock overvalued right now?
Based on GuruFocus' analysis, Shattuck Labs (STTK) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.05, compared to a current price of $7.42 — trading 606.7% above its estimated fair value. The current FCF Margin % is 0.00%. Shattuck Labs' overall GF Score™ is 42/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Shattuck Labs (STTK), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shattuck Labs (STTK) Overvalued in 2026?
Based on GuruFocus' analysis, Shattuck Labs stock appears to be overvalued.
The current stock price of $7.42 is trading 606.7% above its estimated GF Value™ of $1.05.
GuruFocus considers Shattuck Labs to be Significantly Overvalued.
Key valuation signals for STTK:
FCF Margin %: 0.00%
GF Value™: $1.05 vs. price of $7.42 (606.7% above fair value)
No single metric tells the full story. See the STTK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
42GF Score
Get the complete analysis for STTK
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STTK has been successfully added to your 
